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Abstract
We applied RNA arbitrarily primed-PCR (RAP-PCR) to screen the genes differentially expressed between common congenital heart
defects (CHD) [atrial septal defect, ventricular septal defect, Tetrology of Fallot (TOF)] and normal human heart samples. Three of these
differentially amplified fragments matched cDNA sequences coding for proteins of unknown function in humans: hCALO (human
homologue of calossin), NP79 (coding for a nuclear protein of 79KD) and SUN2 (Sad-1 unc-84 domain protein 2). The other four fragments
were from known human genes: apolipoprotein J, titin, dystrophin and protein kinase C-delta. Northern blot analysis confirmed that all of
these genes are expressed in the human heart. The results of RAP-PCR were reconfirmed by quantitative RT-PCR in TOF and control heart
samples. Both techniques showed the levels of expression of hCALO, NP79 and SUN2 to be comparable in TOF and control samples and the
level of expression of dystrophin and titin, both coding for cytoskeletal proteins, to be significantly upregulated in TOF samples. In summary,
we have shown that the RAP-PCR technique is useful in the identification of differentially expressed gene from biopsy samples of human
CHD tissues. In this manner, we have identified three novel genes implicated in the normal function of the human heart and two known genes
upregulated in TOF samples.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Congenital heart defects (CHD) are the most common
form of heart disease in childhood, occurring in about 1% of
live births and perhaps 10% of stillbirths [1]. CHD are the
clinical manifestation of anomalies in heart development, a
complex process requiring cell specification and differentia-
tion, cell migration, morphogenesis and interactions among
cells from a variety of embryonic origins. In recent years,
studies of heart development in fish, frogs, mice, flies and
worms by mutagenesis studies have begun to develop how
morphogenesis and hierarchies of developmental control are
exerted, and have pointed to the role of genes such as the
transcription factors Nkx2-5, GATAs, MEF2s, dHAND and
eHAND [2–5]. However, the basic mechanism for CHD in
man is still incompletely defined.
The paucity of large CHD human families and the
incomplete penetrance of CHD as a phenotype have limited
the usefulness of linkage analysis in identifying causal
genes. Until now, only a few genes directly related to
human CHD have been identified, and most of them are
related to a complex syndrome that includes cardiac mal-
formations, such as TBX5 mutations in Holt Oram syn-
drome [6], TFAP2B mutations in Char syndrome [7], and
the haploinsufficiency of one or more genes in 22q11 or
10p13-p14 that cause DiGeorge Syndrome/velocardiofacial
syndrome (VCFS), two genetic diseases with overlapping
clinical features that include conotruncal defects and abnor-
mal development of other structures derived from the neural
crest [8].
While mutations in the homeobox transcription factor
NKX2.5 gene have been found in patients with nonsyn-
dromic congenital heart diseases [9], it is likely that new
strategies will be required to identify the common non-
syndromic CHD susceptibility genes. The identification of
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genes involved in various stages of cardiac development
will likely be one important step. Another lead may come
from a comparison of gene expression patterns between
normal and CHD hearts or among different types of CHD.
Identification of those differentially expressed genes in
human CHD heart tissues will serve as markers that may
point to the molecular mechanisms involved in normal and
CHD states, and perhaps provide new insights for the
discovery of novel molecular targets for diagnostics and
therapeutics.
RNA arbitrarily primed-PCR (RAP-PCR) [10] and
mRNA differential display (mRNA DD) [11] are two
sensitive PCR-based RNA fingerprinting techniques that
have been successfully applied to many areas including
carcinogenesis, neurobiology, developmental biology and
cardiovascular disease. More than 10 novel genes in car-
diovascular functions and diseases have been discovered by
application of this method [12]. Compared to RAP-PCR,
which preferentially provides internal coding sequences of
differentially expressed genes, cDNA fragments obtained
from mRNA DD methods are often in the 3Vuntranslated
region, and therefore difficult to identify by homology in
databases. In order to find genes related to the pathogenesis
of CHD, we applied RAP-PCR to isolate and characterize
the differentially expressed genes in three common forms of
CHD: atrial septal defect (ASD), ventricular septal defect
(VSD) and Tetrology of Fallot (TOF). We have identified
three interesting sequences that are likely to be related to
normal functioning of the developing and the mature heart.
We also find that the expression of dystrophin and titin, both
coding for a cytoskeletal protein, is significantly upregu-
lated in TOF samples.
2. Methods
2.1. Tissue sources and total RNA preparation
For RAP-PCR, ventricle biopsies were obtained from
six children with CHD during corrective cardiac surgery.
Two of them were with ASD (ages: 6 and 7 years), two
with VSD (ages: 3 and 5 years) and two with TOF (ages:
7 months and 2 years). Ventricle tissue from a 32-year-
old woman with rheumatic heart disease obtained during
her valve-replacement surgery and two biopsies taken
from children (age: 5 and 9 years) with acute cardiac
infections were taken as non-CHD controls. All procedure
conforms to the principles outlined in the Declaration of
Helsinki [Cardiovasc. Res. 35 (1997) 2]. The tissues were
directly frozen in liquid nitrogen and stored at 70 jC
until use. Total RNA was prepared using TRIZOL
Reagent (Life Technologies, New York, USA). Normal
adult (27 years old) and fetal (27 weeks old) RNA
samples were purchased from BioChain Institute, Inc.
As very limited amounts of fresh CHD cardiac biopsy
material were available, only TOF samples that tend to
be larger were chosen to reconfirm the validity of the
RAP-PCR technique using quantitative RT-PCR.
2.2. RAP-PCR
The RNA samples were purified by DNase I treatment
followed by phenol/chloroform extraction and ethanol pre-
cipitation. Two quantities of each total RNA (50 and 100
ng) were reverse transcribed (RT) in a 20 Al reaction mix
with 5 pmol arbitrarily chosen primer 5V-AGCCCGTAGG-
TACCCTGG or 5V-GCAAACCGCGGTGACCACTG to
synthesize first-strand cDNA. The RT reaction was per-
formed with AMV reverse transcriptase and reagents in
Reverse Transcription System (Promega, WI, USA). After-
wards, 10 Al was used for PCR in a 25 Al reaction volume
containing 25 pmol of the same primer as in first-strand
synthesis. PCR was performed with one low stringency
cycle of 94 jC for 5 min, 40 jC for 5 min and 72 jC for 5
min, followed by 39 high stringency cycles of 94 jC for 1
min, 60 jC for 1 min and 72 jC for 2 min in a PTC-100
Thermal Cycler (MJ Research). For nonradioactive RAP-
PCR, the PCR products were electrophoresed in a 6%
nondenaturing polyacrylamide gel, and then stained with
10 Al/100 ml SYBR Green (Boehringer Mannheim, Man-
nheim, Germany) for 30 min. The differentially amplified
bands were cut from the gel under long wavelength UV
light. For radioactive RAP-PCR, the PCR reactions were
performed with 33P end-labeled primers. Then the PCR
products were electrophoresed in a 6% denaturing poly-
acrylamide gel. The gel was dried on a 3M Whatman paper
and exposed to Fuji X-ray film for 24–72 h. Differentially
expressed cDNA bands of interest were cut from the gel and
eluted in 25 Al TE buffer at 65 jC for 2 h. The cDNA bands
isolated by either the radioactive or nonradioactive method
were reamplified with the same PCR conditions and primer.
2.3. cDNA cloning and sequence analysis
cDNA fragments were ligated into pGEM-4Z vector
(Promega) by single-step direct cloning methods [13]. Each
ligation reaction (20 Al) included 200 ng uncut vector
pGEM4Z, 150 ng PCR product, 2U SmaI, 1 unit T4 DNA
polymerase, 0.4 mM dNTPs, 1 unit T4 ligase and ligation
buffer with ATP. The ligation mixture was left overnight at
room temperature, and 5 Al was used for heat shock trans-
formation into the Escherichia coli strain DH5a. Plasmid
DNA was purified using High Pure Plasmid Isolation kit
(Boehinger Mannheim). The presence of insert was tested
by digestion with EcoRI. Successfully cloned cDNA frag-
ments were sequenced with M13 forward primers in an ABI
PRISM 377 automatic sequencing machine (Applied Bio-
systems, Foster City, CA) using the ABI Prism dRhodamine
Terminator Cycle Sequencing kit. Homology search was
performed using the BLAST algorithm in the nonredundant
database of the National Center for Biotechnology Informa-
tion.
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2.4. Northern blot analysis
The cDNA inserts were released from plasmids with
restriction enzymes and purified by QIAEX II Gel Extrac-
tion Kit (Qiagen). Then, the DNA fragment was labeled
with a-32P-dCTP (3000 Ci/mmol) by random primer label-
ing [14]. Premade human multiple-tissue blot and fetal
multiple-tissue blot II were purchased from Invitrogen
(Carlsbad, CA). The manufacturer’s information indicated
that each lane was loaded with 20 Ag of total RNA from
eight different male tissues including adult heart, brain,
kidney, liver, lung, pancreas, spleen, skeletal muscle for
human multiple tissue blot; and from human fetal heart,
kidney, stomach and intestine for fetal blot II. Filters were
hybridized with the labeled probe, washed and exposed to
X-ray film (Fuji) at 70 jC with two intensifying screens.
Blots were stripped with 0.5% SDS at 95 jC, and rehybri-
dized with labeled glyceraldehyde-3-phosphate dehydrogen-
ase (GAPDH) probe as a standard to allow calibration for
actual mRNA loading difference.
2.5. Relative quantitation of gene expression by RT-PCR
For first-strand cDNA synthesis, 5 Ag of total RNA
(DNase treated) was reverse transcribed with 250 pmol
random hexamers and 400 units Superscript II (Life Tech-
nologies) in a 100 Al reaction following manufacturer’s
instructions. The resulting cDNA (from 50 ng total RNA
per Al) was stored at 70 jC until use. Relative quantitation
was done using the comparative CT method with SYBR
Green PCR Core Reagents (Applied Biosystems) according
to manufacturer’s protocol (User Bulletin #2, ABI PRISM
7700 Sequence Detection System, Applied Biosystems).
GAPDH was used as the reference internal control. A panel
of serially diluted cDNA (50, 5 and 0.5 ng, and 50 pg total
RNA) was used to check the consistency of relative ampli-
fication efficiency of the target and reference. Quantitative
PCR was carried out with an ABI PRISM 7700 Sequence
Detector (Applied Biosystems) in a 25 Al reaction with 5 ng
of cDNA, 5 pmol each of forward and reverse primer (Table
1), 3 mM MgCl2, 200 AM dATP, dCTP, dGTP, 400 AM
dUTP, 0.625 unit AmpliTaq Gold and 0.25 unit AmpErase
UNG. The PCR cycling condition was 2 min at 50 jC for
AmpErase UNG incubation, 10 min at 95 jC for AmpliTaq
Gold activation, followed by 40 cycles of 15 s at 95 jC, 15 s
at 60 jC and 30 s at 70 jC. An aliquot of PCR product was
checked for a single specific band by electrophoresis.
3. Results
3.1. RAP-PCR
RAP-PCR was performed using total RNA isolated from
ASD, VSD, TOF and non-CHD ventricle biopsies. To avoid
differential amplification caused by concentration or quality
differences among RNA samples, two concentrations of
RNA were tested for each RNA sample. Only differentially
amplified products present in both concentrations were
selected. RAP-PCR with radioisotope-labeled primer pro-
duced approximately 200 resolved products in a 40-cm gel.
Six well-resolved differentially expressed cDNA fragments
(R1–R6) were selected and excised from the gel. Non-
radioactive RAP-PCR yielded approximately 100 resolved
bands in a 15-cm gel. Nine well-resolved differentially
expressed fragments (NR1–NR9) were isolated under direct
UV light visualization.
3.2. Sequence analysis of the differentially amplified cDNA
fragments
The cDNA fragments were cloned and sequenced.
Homology search was performed and the results are sum-
marized in Table 2. The six differentially amplified frag-
ments isolated with the radiolabeled primer were: Human
apolipoprotein J mRNA, Homo sapiens mRNA for
KIAA0462 protein (referred to as hCALO for human
homologue of Drosophila calossin), H. sapiens mRNA for
KIAA0668 protein or sad1 unc-84 domain protein 2
(referred to as SUN2). The remaining three were homolo-
gous to 28s ribosomal RNA sequence. Using nonradiola-
beled primer, nine differentially amplified cDNA fragments
were isolated and studied further. Homology search revealed
those to be: titin, dystrophin, protein kinase C-delta 13 and
HRIHFB2216 mRNA, a sequence recently reported to be a
cutaneous T-cell lymphoma-associated antigen. Since we
have found HRIHF2216 mRNA encodes a putative nuclear
localization protein of predicted molecular weight 79 kDa
(see discussion), we referred to it as NP79. The remaining
five cDNAs were ribosomal RNA and mitochondrial RNA.
In the RAP-PCR fingerprint, hCALO, NP79, SUN2, protein
kinase C-delta and apolipoprotein J showed a higher expres-
sion in VSD samples. On the other hand, titin and dystro-
phin showed a higher expression in TOF samples.
Table 1
Sequences of primer pairs for PCR
Gene Primer pair
(5Vto 3V)
Amplicon length
(bp)
GAPDH ACCACAGTCCATGCCATCAC 452
(reference) TCCACCACCCTGTTGCTGTA
Titin CAAGGACACCAAGTGCACAG 148
TGGTCCAGGAGTGGTAAAGG
Dystrophin GACCAGCACAACCTCAAGCA 151
TCAGCAGCCAGTTCAGACACA
hCALO CATGGCAATGAGGCAGAAGG 103
CAGCTCTTCCATCTGCTTCAGG
NP79 TTCCGCTACTTGACCAATCTGC 126
GCGCTGGAACTCCTTGACAAT
SUN2 CCGTTACCTTAGAGCATGTGCC 148
TCGCCGTCCTGATCGTAAGT
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3.3. Northern blot analysis
The expression patterns of the three functionally
unknown genes (hCALO, NP79 and SUN2) in adult and
fetal tissues were studied using Northern blots (Fig. 1). It
can be seen that although equal amounts of total RNA were
loaded, as reported by the manufacturer, the GAPDH signal
in lung and pancreas was reduced, reflecting tissue differ-
ences in these mRNA abundance in these tissues (Invitro-
gen). hCALO is identical to H. sapiens mRNA for
KIAA0462 protein, with 7150 bases reported. Northern blot
analysis of this novel sequence revealed a transcript longer
than 9 kilobases (kb) detected only in adult heart, brain and
lung. The transcript of NP79 was 2.8 kb and was strongly
expressed in adult heart, moderately in brain, lung and
spleen, and weakly in kidney and skeletal muscle. Interest-
ingly, the expression of NP79 in adult heart was stronger
than in fetal heart while the converse was observed in
kidney. Another differentially amplified gene, SUN2, dem-
onstrated constitutive expression of a 3.8 kb transcript in
various tissues, with strongest expression in adult heart,
lung and muscle. By Northern blot analysis, protein kinase
C-delta 13 and apolipoprotein J were found to be constitu-
tively expressed in various adult and fetal tissues and TOF
biopsies (data not shown).
3.4. Relative quantitation of gene expression by RT-PCR
Only ventricle biopsies from TOF patients yielded suffi-
cient RNA for further analysis. Amplification curves from
serial dilution of cDNA show that the CT value (threshold
cycle) correlated with the concentration of the gene under
investigation within the cDNA range from 50 ng to 50 pg
total RNA. The amount of cDNA used in quantitative PCR
(from 5 ng of total RNA) falls in the mid range, suggesting
that PCR should not be saturated in this study (data not
shown). The relative expressions of genes in this study are
shown in Fig. 2. The relative expression of each gene in the
adult heart sample was used for normalization. Both titin
and dystrophin showed a higher expression in TOF samples
in the RAP-PCR fingerprint. The levels of expression of
titin in adult and fetal hearts were similar (1.00F0.03 and
0.94F0.07). Both TOF samples were found to have higher
expression of titin when compared to the normal adult
sample (1.60F0.12 and 3.00F0.16). For dystrophin, fetal
(1.61F0.11) and TOF samples (1.49F0.11 and 2.24F0.12)
both had a higher expression relative to the adult sample
(1.00F0.04). hCALO, NP79 and SUN2, which were found
to be upregulated in VSD samples in the RNA fingerprint,
had expression levels similar to that of the adult heart (Fig.
2), but all three genes had different levels of expression in
the adult and fetal heart. In agreement with the results of
Northern analysis, NP79 and SUN2 were expressed at a
higher level in the adult heart than the fetal heart (1.00F0.11
vs. 0.42F0.1; 1.00F0.17 vs. 0.33F0.05, respectively).
However, hCALO was found to have a higher level of
expression in the fetal heart by RT-PCR (1.00F0.42 vs.
Fig. 1. Northern analysis of the sequences identified by RAP-PCR. RNA
(20 Ag) from the tissues indicated were loaded. hCALO, NP79 and SUN2
all showed a higher expression in adult than in fetal heart. The same filters
were used for all probes. Hybridization with GAPDH was done lastly to
indicate RNA loading. Positions of the RNA marker bands were indicated
to the right.
Table 2
Homology search results of cloned cDNA fragments from RAP-PCR
Fragment Size (bp) Name Accession number Description
R1 310 ApoJ J02908 Human apolipoprotein J mRNA, complete cds (1512 bp)
R2 406 hCALO AB007931 Homo sapiens mRNA for KIAA0462 protein, partial cds (7150 bp)
R3 173 SUN2 AF202723 Homo sapiens Sad1 unc-84 domain protein 2 (SUN2) mRNA, partial cds (1323 bp)
AB014568 Homo sapiens mRNA for KIAA0668 protein, partial cds (3767 bp)
R4-R6 – – – Ribosomal RNA
NR1 162 titin X90568 Homo sapiens mRNA for titin protein (81940 bp)
NR2 412 dystrophin M18533 Homo sapiens dystrophin (DMD) mRNA, complete cds (13957 bp)
NR3 300 PKC-y L07860 Human protein kinase C-delta 13 mRNA, complete cds (2104 bp)
NR4 388 NP79 AB015345 Homo sapiens HRIHFB2216 mRNA, partial cds (1605 bp)
AF273046 Homo sapiens CTCL tumor antigen se20-4 mRNA, complete cds (2830 bp)
NR5–NR9 – – – Ribosomal RNA and mitochondrial RNA
G. Sun et al. / Biochimica et Biophysica Acta 1588 (2002) 241–246244
2.14F0.66). Since the RNA of hCALO is >15 kb, the
transcripts might be transferred inefficiently to the filter
during northern analysis.
4. Discussion
Defects in heart septation, including ASD, VSD, atrio-
ventricular septal defects and TOF, represent major causes
of CHD [10]. They commonly involve ventricular or pres-
sure overload hypertrophy before evolving into compen-
sated congestive heart failure. Since differential gene
expression is likely essential for normal heart development
and pathological processes [2,10], the discovery of differ-
entially expressed genes may provide a window for under-
standing the molecular mechanisms involved in normal and
pathological states. In an attempt to begin the process of
discovering those genes, we investigated a number of the
genes that are differentially expressed in RNA samples from
ASD, VSD, TOF and non-CHD controls by RAP-PCR.
Among these differentially expressed genes resolved, three
lack functional characterization (hCALO, NP79 and SUN2),
while four are homologous to known genes.
hCALO is identical to H. sapiens brain mRNA for
KIAA0462 protein, although the complete cDNA sequence
has not been characterized yet [15]. The amino acid
sequence of KIAA0462 (2276 amino acids) shows 45%
identity and 64% similarity to the pushover protein of
Drosophila melanogaster. The pushover gene codes for a
large protein of 5322 amino acids that affects synaptic
transmission at the neuromuscular junction. Mutations in
pushover affect both neuronal excitability and the process of
transmitter release [16]. Pushover is identical to calossin, a
novel calmodulin protein in Drosophila retina that is highly
conserved through animal phylogeny. The CALO mRNA is
of 15–20 kb on Northern blots [17]. We named the gene we
found in heart tissue hCALO for human homologue of
calossin. The human transcript we identified is also much
larger than 9 kb and is detected specifically in adult heart,
brain and lung by Northern blotting. Since calmodulin is an
important Ca2+ sensor and Ca2+ influx regulates multiple
cellular events, the tissue specificity and sequence conser-
vation of hCALO suggests a possible role in regulating
cardiac function.
NP79 is identical to H. sapiens HRIHFB2216 mRNA. A
partial HRIHFB2216 cDNA of 1605 bases was found to
encode a nuclear targeted protein containing nuclear local-
ization signals [18]. As a step towards identifying its
function, we have isolated the cDNA by screening a human
adult heart cDNA library. Complete sequencing of the 2.8
kb insert indicates that it is identical to a clone for cutaneous
T-cell lymphoma-associated antigen isolated from a normal
testis cDNA library using the method of ‘serological iden-
tification of recombinantly expressed genes’ [19]. The
predicted protein encoded by the complete cDNA sequence
has 693 amino acids, a molecular weight of 79 kDa and a
nucleosome assembly domain. A fusion protein of our
cDNA clone and the green fluorescent protein revealed
Fig. 2. Quantitative RT-PCR analysis of different genes on adult, fetal and TOF samples. Values are presented in relative expression level to adult tissue, which
is normalized with GAPDH (DDCT method). Height of bars and the error bars represent the mean value and 95% confident intervals based on quadruplicate
results.
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the same nuclear localization pattern as originally reported
for the partial cDNA [18] (not shown). As NP79 is highly
expressed in the adult heart, it is a promising candidate for
further evaluation of its role in maintaining human cardiac
function.
Blast analysis revealed that H. sapiens mRNA for
KIAA0668 protein is identical to the coding region of H.
sapiens Sad 1 unc-84 domain protein 2 (SUN2) mRNA
(with only 1323 bases being reported) [20]. SUN2 is the
human homologue of C. elegans unc-84, a gene required for
the nuclear migrations that occurs during development of
the worm [20]. This sequence is of particular interest since
the gene functions of SUN2 in man are still not character-
ized and because it maps to 22q12-13, a region adjacent to
the major chromosome region of microdeletions associated
with cardiac and craniofacial defects [21].
The mRNA for titin is 81,940-bp long and codes for the
largest protein known [22]. Titin, also known as connectin,
is an integral cytoskeletal protein with a molecular weight of
approximately 3 million Dalton. It is a relatively abundant
protein comprising f10% of the myofibril mass. Titin is
essential in the control of the assembly of the highly ordered
sacromeres, and mutations in this gene cause autosomal
dominant familial dilated cardiomyopathy [23]. The possi-
ble function of titin is to hold myosin filaments together at
the center of the sarcomere, equidistant from the adjacent Z
lines, and to provide structural continuity in relaxed myofi-
brils [24]. An increase in titin mRNA with hypertrophy and
loss of titin in heart failure were reported in guinea pigs
[25]. Here we report a 1.5- and 3-fold increase in the level of
expression of titin in TOF samples compared with normal
heart. Dystrophin is also a cytoskeletal protein that is
involved in fixation of sarcomeres to the lateral sarcolemma
and stabilization of the transverse (T)-tubular system. In
adult cardiac muscle, dystrophin is also localized on T-
tubules. Like titin, we find an increase in dystrophin
expression in TOF samples compared to the adult heart.
Altered expression of the membrane-associated protein
dystrophin might be associated with cardiac hypertrophy
and failure [26]. While it would be ideal to have more
perfect matched controls and a larger sample size, our
results support the hypothesis that in cardiac hypertrophy
and failure, the early and reversible stage is characterized by
accumulation of cytoskeletal proteins to counteract the
increased strain [26].
In conclusion, we have applied RAP-PCR to identify
differentially expressed genes in human normal and CHD
heart tissues. We found nonradioactive RAP-PCR a con-
venient and safe method. The validity of the method was
confirmed by our observation that dystrophin and titin were
of expressed at increased levels in TOF samples using both
RAP-PCR and quantitative PCR. All three functionally
unknown genes studied show a higher level of expression
in VSD samples in the RAP-PCR fingerprint and have
changing level of expression during normal human heart
development. The predicted proteins suggest that they may
have significant roles in heart development and function.
Further investigation of their normal functions is underway
using their mouse homologues.
Acknowledgements
We thank Becky Cheung (HKU) for excellent technical
assistance, Dr. Mary Waye (CUHK) and Dr. J. Jay Gargus
(UC, Irvine) for constructive comments and proofreading on
the manuscript. G.F. Sun was a recipient of Dr. Cheng Yu
Tung Fellowship, Hong Kong. This work was supported by
the National Nature Science Foundation of China (G.F. Sun)
and the University of Hong Kong (M.P. Leung).
References
[1] J.I. Hoffman, Pediatr. Cardiol. 16 (1995) 103–113.
[2] D. Srivastava, E.N. Olson, Nature 407 (2000) 221–226.
[3] K.R. Chien, Nature 407 (2000) 227–232.
[4] J.N. Chen, M.C. Fishman, Trends Genet. 16 (2000) 383–388.
[5] D. Srivastava, Trends Cardiovasc. Med. 9 (1999) 11–18.
[6] Q.Y. Li, R.A. Newbury-Ecob, J.A. Terrett, D.I. Wilson, A.R. Curtis,
C.H. Yi, T. Gebuhr, P.J. Bullen, S.C. Robson, T. Strachan, D. Bonnet,
S. Lyonnet, I.D. Young, J.A. Raeburn, A.J. Buckler, D.J. Law, J.D.
Brook, Nat. Genet. 15 (1997) 21–29.
[7] M. Satoda, F. Zhao, G.A. Diaz, J. Burn, J. Goodship, H.R. Davidson,
M.E. Pierpont, B.D. Gelb, Nat. Genet. 25 (2000) 42–46.
[8] S. Schiaffino, B. Dallapiccola, R. Di Lisi, Circ. Res. 84 (1999)
247–249.
[9] J.J. Schott, D.W. Benson, C.T. Basson, W. Pease, G.M. Silberbach,
J.P. Moak, B.J. Maron, C.E. Seidman, J.G. Seidman, Science 281
(1998) 108–111.
[10] J. Welsh, K. Chada, S.S. Dalal, R. Cheng, D. Ralph, M. McClelland,
Nucleic Acids Res. 19 (1992) 4965–4970.
[11] P. Liang, A.B. Pardee, Science 257 (1992) 967–970.
[12] X. Wang, G.Z. Feuerstein, Cardiovasc. Res. 35 (1997) 414–421.
[13] S.E. Chuang, K.C. Wang, A.L. Cheng, Trends Genet. 11 (1995) 7.
[14] A.P. Feinberg, B. Vogelstein, Anal. Biochem. 132 (1983) 6–13.
[15] O. Ohara, DNA Res. 4 (1997) 345–349.
[16] S. Richard, T. Hillman, M. Stern, Genetics 142 (1996) 1215–1523.
[17] X.Z. Xu, P.D. We, H. Chen, H.S. Li, M. Yu, S. Morgan, Y. Liu, C.
Montell, J. Biol. Chem. 273 (1998) 31297–31307.
[18] N. Ueki, T. Oda, M. Kondo, K. Yano, T. Noguchi, M. Muramatsu,
Nat. Biotechnol. 16 (1998) 1338–1342.
[19] S. Eichmuller, D. Usener, R. Dummer, A. Stein, D. Thiel, D. Scha-
dendorf, Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 629–634.
[20] C. Malone, W. Fixsen, H. Horvitz, M. Han, Development 126 (1999)
3171–3181.
[21] H. Yamagishi, V. Garg, R. Matsuoka, T. Thomas, D. Srivastava,
Science 283 (1999) 1158–1161.
[22] S. Labeit, B. Kolmerer, W.A. Linke, Circ. Res. 80 (1997) 290–294.
[23] B. Gerull, M. Gramlich, J. Atherton, M. McNabb, K. Trombitas, S.
Sasse-Klaassen, J.G. Seidman, C. Seidman, H. Granzier, S. Labeit, M.
Frenneaux, L. Thierfelder, Nat. Genet. 30 (2002) 201–204.
[24] B. Kolmerer, C.C. Witt, A. Freiburg, S. Millevoi, G. Stier, H. Sori-
machi, K. Pelin, L. Carrier, K. Schwartz, D. Labeit, C.C. Gregorio,
W.A. Linke, S. Labeit, Rev. Physiol., Biochem. Pharmacol. 138
(1999) 19–55.
[25] J.F. Collins, C. Pawloski-Dahm, M.G. Davis, N. Ball , G.W. Dorn II,
R.A. Walsh, J. Mol. Cell. Cardiol. 28 (1996) 1435–1443.
[26] S. Hein, S. Kostin, A. Heling, Y. Maeno, J. Schaper, Cardiovasc. Res.
45 (2000) 273–278.
G. Sun et al. / Biochimica et Biophysica Acta 1588 (2002) 241–246246
